We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

37 hedge funds and large institutions have $16.6M invested in Matinas BioPharma in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

0.13% less ownership

Funds ownership: 0.45% → 0.32% (-0.13%)

21% less funds holding

Funds holding: 47 → 37 (-10)

40% less capital invested

Capital invested by funds: $27.7M → $16.6M (-$11.1M)

59% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 17

Holders
37
Holders Change
-10
Holders Change %
-21.28%
% of All Funds
0.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
4
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$1.43M
2
SCA
STALEY CAPITAL ADVISERS
Pennsylvania
+$145K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$133K
4
WG
Winton Group
United Kingdom
+$126K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$88.4K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$5.84M
2
BC
Broadfin Capital
New York
-$657K
3
SCM
Stonepine Capital Management
Oregon
-$573K
4
Millennium Management
Millennium Management
New York
-$132K
5
TI
Telemetry Investments
New York
-$103K
Name Holding Trade Value Shares
Change 		Change in
Stake
RJA
26
Raymond James & Associates
Florida
$11K +$3.25K +90 +36%
Commonwealth Equity Services
27
Commonwealth Equity Services
Massachusetts
$10K – – –
OAM
28
Oxford Asset Management
United Kingdom
$10K +$11.2K +310 New
Two Sigma Investments
29
Two Sigma Investments
New York
$7K +$8.13K +225 New
CFS
30
CRA Financial Services
New Jersey
$6K – – –
FC
31
Fore Capital
New York
$6K – – –
GIA
32
Gladstone Institutional Advisory
Florida
$6K +$7.23K +200 New
AG
33
Advisor Group
Arizona
$3K – – –
HFM
34
Hartford Financial Management
Connecticut
$2K – – –
Fidelity Investments
35
Fidelity Investments
Massachusetts
$1K +$867 +24 New
BNP Paribas Financial Markets
36
BNP Paribas Financial Markets
France
$17 – – –
VC
37
Vivo Capital
California
– -$5.84M -136,364 Closed
BC
38
Broadfin Capital
New York
– -$657K -15,334 Closed
SCM
39
Stonepine Capital Management
Oregon
– -$573K -13,372 Closed
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
– -$77K -1,803 Closed
SSA
41
Schonfeld Strategic Advisors
New York
– -$46K -1,068 Closed
Jane Street
42
Jane Street
New York
– -$31K -732 Closed
JMPWA
43
JP Morgan Private Wealth Advisors
California
– -$26K -600 Closed
VF
44
Virtu Financial
New York
– -$25K -594 Closed
D.E. Shaw & Co
45
D.E. Shaw & Co
New York
– -$24K -550 Closed
AWM
46
AE Wealth Management
Kansas
– -$17K -399 Closed
SS
47
Simplicity Solutions
Minnesota
– -$17K -399 Closed
ARTA
48
A.R.T. Advisors
New York
– -$14K -316 Closed
USAA
49
United Services Automobile Association
Texas
– -$10K -224 Closed
IIA
50
IPG Investment Advisors
California
– -$8.57K -200 Closed
1
2
3

MTNB Hedge Fund Activity: Q3 2019 in Review

37 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2019, worth a combined $16.6M — down 40% from $27.7M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of MTNB and 7 opened new positions — a net loss of 10 holders — while 4 trimmed existing stakes and 8 added.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $1.43M. The largest seller was Vivo Capital, exiting entirely with an estimated $5.84M sold.

  • 37 institutional investors held Matinas BioPharma (MTNB) as of Q3 2019, down from 47 in Q2 2019.
  • Funds reported $16.6M of Matinas BioPharma stock for Q3 2019, down 40% quarter-over-quarter.
  • 7 funds opened new Matinas BioPharma positions in Q3 2019 and 17 closed out, a net change of -10 holders.
  • The largest Matinas BioPharma buyer in Q3 2019 was Baker Bros. Advisors, an estimated $1.43M added.
  • The largest Matinas BioPharma seller in Q3 2019 was Vivo Capital, an estimated $5.84M sold.

Based on aggregated 13F filings for Q3 2019.